IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability

IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability

Psoriasis is a chronic, immune-mediated skin condition with systemic involvement, frequently requiring long-term treatment. At present, there are 11 biologic agents available for the treatment of moderate-to-severe psoriasis, which target specific inflammatory cytokines involved in the immunopathoge...

Full description

Bibliographic Details
Main Authors: Sima D. Amin, Annika S. Silfvast-Kaiser, So Yeon Paek, Dario Kivelevitch, Alan Menter
Format: Article
Language:English
Published: European Medical Journal 2019-11-01
Series:European Medical Journal Dermatology
Subjects:
biologics
il-23 inhibitors
psoriasis
Online Access:https://www.emjreviews.com/dermatology/article/il-23-inhibitors-for-moderate-to-severe-plaque-psoriasis-a-review-of-clinical-efficacy-safety-and-tolerability/

Internet

https://www.emjreviews.com/dermatology/article/il-23-inhibitors-for-moderate-to-severe-plaque-psoriasis-a-review-of-clinical-efficacy-safety-and-tolerability/

Similar Items